Chemical Namepanobinostat lactate
Dosage FormCapsule (oral; 10 mg, 15 mg, 20 mg)
Drug ClassInhibitors
Approval Year2015


  • In combination with bortezomib and dexamethasone, is indicated for the treatment of patients with multiple myeloma who have received at least 2 prior regimens, including bortezomib and an immunomodulatory agent.
Last updated on 10/9/2020

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Farydak (panobinostat lactate) Prescribing Information 2019Secura Bio, Inc., Las Vegas, NV
Document TitleYearSource
Panobinostat for treating multiple myeloma after at least 2 previous treatments. 2016NICE Technology appraisal guidance